Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- How India's decision to not join major trade pacts can help its aim of being a 5-trillion economy
- Budget expectations: Increased use of technology, export-promoting measures and reduced crop insurance premiums
- Mimicking the brain! Why neuromorphic computing can redefine the IoT
- Govt officials, industry experts brainstorm on use of AI for public grievances redressal
